887035-85-0

Usage

Explanation

The compound's full name, which describes its structure and functional groups.

Explanation

A shorter, more common name used to refer to the compound.

Explanation

FMCA belongs to the class of carboxylic acids, which are organic compounds containing a carboxyl group (-COOH).

Explanation

FMCA contains a 1,2,3-triazole ring, which is known for its diverse and important biological activities.

Explanation

The presence of a carboxyl group in FMCA, which is characteristic of carboxylic acids.

Explanation

FMCA has a fluorine atom substituted at the 2nd position of the phenyl ring, which can influence its biological activity and properties.

Explanation

FMCA has a methyl group (-CH3) at the 5th position of the triazole ring, which can affect its steric and electronic properties.

Explanation

FMCA has potential pharmaceutical applications, particularly in the development of new drugs for the treatment of cancer and infectious diseases.

Explanation

FMCA is of interest to researchers for its potential use in the development of new drugs due to its unique molecular structure and functional groups.

Explanation

The triazole ring present in FMCA is known for its diverse and important biological activities, which makes it a promising candidate for further research and development in the pharmaceutical industry.

Class

Carboxylic Acids

Structural Feature

Triazole Ring

Functional Group

Carboxyl Group (-COOH)

Fluorine Substitution

2-fluorophenyl

Methyl Substitution

5-methyl

Potential Applications

Pharmaceutical Industry

Research Interest

Drug Development

Biological Activity

Diverse and Important

Upstream product

• 348-54-9 2-Fluoroaniline 
• 3296-04-6 1-azido-2-fluorobenzene 
• 141-97-9 ethyl acetoacetate 
• 1993-03-9 o-fluorophenylboronic acid 
• 1147189-40-9 C₁₂H₁₂FN₃O₂ 

Downstream Products

• 895093-36-4 5-[1-(2-fluorophenyl)-5-methyl-1H-1,2,3-triazol-4-yl]-3-phenyl-1,2,4-oxadiazole 
• 1166828-18-7 3-(2-fluorophenyl)-5-[1-(2-fluorophenyl)-5-methyl-1H-1,2,3-triazole-4-yl]-1,2,4-oxadiazole 
• 2131223-69-1 1-(2-fluorophenyl)-5-methyl-N-(quinolin-2-yl)-1H-1,2,3-triazole-4-carboxamide 

Relevant academic research and scientific papers

Primary discovery of 1-aryl-5-substituted-1H-1,2,3-triazole-4-carboxamides as promising antimicrobial agents

Three series of novel 1H-1,2,3-triazole-4-carboxamides: 1-aryl-5-alkyl/aryl-1H-1,2,3-triazole-4-carboxamides, 1-aryl-5-amino-1H-1,2,3-triazole-4-carboxamides and 1,2,3-triazolo[1,5-a]quinazoline-3-carboxamides were synthesized via base-mediated click azide reactions. Compounds were evaluated for their antimicrobial activities against primary pathogens: Gram-positive and Gram-negative bacterial strains Escherichia coli, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, as well as fungal strain Cryptococcus neoformans var. grubii and Candida albicans. Compounds exhibiting moderate to good activities were selected for SAR analysis. Several 5-methyl-1H-1,2,3-triazole-4-carboxamides 4d, 4l, 4r, showed potent antibacterial effect against S. aureus. On the contrary, 5-amino-1H-1,2,3-triazole-4-carboxamide 8b and [1,2,3]triazolo[1,5-a]quinazoline-3-carboxamide 9a were active against pathogenic yeast C. albicans. Thus, compound 4l under 1 μM demonstrated 50% growth inhibition against S. aureus. At the same concentration, the compound 9a killed approx. 40% of C. albicans cells. In general, these compounds demonstrated selective action and no significant impact on the viability of human keratinocytes of HaCaT line.

Triazole-Based Inhibitors of the Wnt/β-Catenin Signaling Pathway Improve Glucose and Lipid Metabolisms in Diet-Induced Obese Mice

Wnt/β-catenin signaling pathway is implicated in the etiology and progression of metabolic disorders. Although lines of genetic evidence suggest that blockage of this pathway yields favorable outcomes in treating such ailments, few inhibitors have been used to validate the promising genetic findings. Here, we synthesized and characterized a novel class of triazole-based Wnt/β-catenin signaling inhibitors and assessed their effects on energy metabolism. One of the top inhibitors, compound 3a, promoted Axin stabilization, which led to the proteasome degradation of β-catenin and subsequent inhibition of the Wnt/β-catenin signaling in cells. Treatment of hepatocytes and high fat diet-fed mice with compound 3a resulted in significantly decreased hepatic lipid accumulation. Moreover, compound 3a improved glucose tolerance of high fat diet-fed mice without noticeable toxicity, while downregulating the genes involved in the glucose and fatty acid anabolisms. The new inhibitors are expected to be further developed for the treatment of metabolic disorders.

PYRROLOPYRIMIDINES AS CFTR POTENTIATORS

The present invention relates to compounds of Formula I, wherein R1a, R1b, R2, R3, R4, W, Y, and Z are as described herein, and pharmaceutically acceptable salts thereof. The compounds are potentiator

WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE

Compounds and compositions are provided as inhibitors of the Wnt/β-catenin pathway for the treatment of diseases that implicate the same.

Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors

A series of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety were designed, synthesized, and evaluated for their c-Met kinase inhibitory activities and antiproliferative activities against 4 cancer cell lines (HT-29, A549, MCF-7, and PC-3) in vitro. Most compounds showed moderate to excellent potency, with the most promising analog 34 showing a c-Met IC50value of 1.68?nM. Structure–activity relationship studies indicated that electron-withdrawing groups (X?=?CF3, R1?=?F, R2?=?4-F) were required to decrease the higher electron density on the 5-atom linker to a proper degree to improve the inhibitory activity.

Heterocyclic compound and use thereof

Compounds represented by the formulas wherein each symbol is as defined in the specification, and a prodrug thereof have a superior renin inhibitory activity, and are useful as agents for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like.

TRIAZOLE OXADIAZOLES DERIVATIVES

The invention relates to compounds of formula (I), wherein R1, R2, Ra, Rb, X have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.